HEICO Corp. 10-Q Summary: Quarter Ended January 31, 1996
Business Context and Reporting Period
This Form 10-Q covers the three-month period ended January 31, 1996 (Fiscal Q1 1996). HEICO Corporation operates through two primary segments: HEICO Aerospace Corporation (aerospace products and services) and MediTek Health Corporation (health care services). The company reported 2,834,522 shares of common stock outstanding as of February 29, 1996.
Key Financial Metrics
| Metric | Q1 1996 | Q1 1995 |
|---|---|---|
| Net Sales | $10,860,000 | $8,933,000 |
| Net Income | $870,000 | $569,000 |
| Earnings Per Share (Diluted) | $0.28 | $0.20 |
| Operating Income | $1,327,000 | $909,000 |
| Cash from Operations | $1,022,000 | $729,000 |
| Cash and Equivalents (End of Period) | $7,591,000 | $3,497,000 |
| Total Debt (Current + Long-term) | $6,952,000 | $N/A (Not explicitly summed in text) |
| Effective Tax Rate | 36.8% | 39.3% |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 22% year-over-year, driven by a 29% surge in HEICO Aerospace sales ($6.98M vs. $5.39M) and a 10% increase in MediTek sales ($3.88M vs. $3.54M).
- Profitability: Net income rose 53% to $870,000. Operating income increased 46% to $1.33M.
- Margins: HEICO Aerospace gross margins improved to 33.3% from 32.3% due to favorable product mix and cost reductions. Conversely, MediTek gross margins declined to 24.8% from 34.5% due to increased contractual allowances in certain regions.
- Partnership Income: Equity in income of unconsolidated partnerships swung from a $175,000 loss in Q1 1995 to a $114,000 gain in Q1 1996, largely due to the merger of an unprofitable center.
- Liquidity: Cash and cash equivalents increased by $2.93M, aided by the maturity of $2.94M in short-term investments and strong operating cash flow.
Outlook, Risks, and Management Commentary
- Backlog: HEICO Aerospace backlog stands at approximately $24 million as of January 31, 1996, up from $13 million a year prior. This includes $14 million in forecasted shipments for specific contracts.
- Capital Allocation: The company utilized cash for $523,000 in property, plant, and equipment purchases and $425,000 in contingent note payments related to prior acquisitions. Dividends of $0.075 per share were paid.
- Accounting Standards: Management noted the issuance of SFAS No. 123 regarding stock-based compensation. The company has not yet determined if it will elect to recognize compensation expense under the new standard, which applies starting fiscal year 1997.
- Risks: MediTek's margins remain sensitive to contractual allowances from third-party reimbursement sources. No material legal proceedings were reported.
Investor Verification Checklist
- Verify the sustainability of HEICO Aerospace's 29% sales growth and the $24 million backlog composition.
- Monitor MediTek's gross margin recovery, specifically regarding contractual allowances in key geographic regions.
- Confirm the impact of the merger of unconsolidated partnerships on future equity income stability.
- Review the company's decision on adopting SFAS No. 123 for stock-based compensation in future filings.
- Track debt repayment schedules, noting the current maturities of $778,000 and long-term debt of $6.17M.